Search Clinical Trials
Sponsor Condition of Interest |
---|
YES Study - Newly Diagnosed/Metastatic Intervention
Dana-Farber Cancer Institute
Breast Cancer
Symptom, Behavioral
This research study is being done to monitor common symptoms and behavior, and to provide
supportive care information and peer support, as well as research opportunities for young
women ages of 18-39 years old who have been diagnosed with stage 0-IV stage breast cancer
using a web-based portal (YES),... expand
This research study is being done to monitor common symptoms and behavior, and to provide supportive care information and peer support, as well as research opportunities for young women ages of 18-39 years old who have been diagnosed with stage 0-IV stage breast cancer using a web-based portal (YES), built for smartphones, tablets, and computers. Type: Interventional Start Date: Sep 2020 |
Medtronic Terminate AF Study
Medtronic Cardiac Surgery
Persistent Atrial Fibrillation
Longstanding Persistent Atrial Fibrillation
The purpose of this study is to demonstrate the safety and effectiveness of the
Cardioblate iRF and CryoFlex hand held devices for the treatment of non-paroxysmal AF. expand
The purpose of this study is to demonstrate the safety and effectiveness of the Cardioblate iRF and CryoFlex hand held devices for the treatment of non-paroxysmal AF. Type: Interventional Start Date: Nov 2018 |
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid...
ModernaTX, Inc.
Solid Tumors
The purpose of this study is to assess the safety, tolerability, and immunogenicity of
mRNA-4157 alone and in combination in participants with solid tumors. expand
The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors. Type: Interventional Start Date: Aug 2017 |
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Karyopharm Therapeutics Inc
Multiple Myeloma
This study will independently assess the efficacy and safety of 11 combination therapies
in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of
patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple
myeloma (NDMM). The combinations to... expand
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: - Arm 1: Selinexor + dexamethasone + pomalidomide (SPd); enrollment complete - Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete - Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete - Arm 4: Selinexor + dexamethasone + pomalidomide + bortezomib (SPVd); enrollment complete - Arm 5: Selinexor + dexamethasone + daratumumab (SDd); enrollment complete - Arm 6: Selinexor + dexamethasone + carfilzomib (SKd); enrollment complete - Arm 7: Selinexor + dexamethasone + lenalidomide (SRd) in NDMM; enrollment complete - Arm 8: Selinexor + dexamethasone + ixazomib (SNd); enrollment complete - Arm 9: Selinexor + dexamethasone + pomalidomide + elotuzumab (SPEd); enrollment complete - Arm 10: Selinexor + dexamethasone + belantamab mafodotin (SBd); enrollment complete - Arm 11: Selinexor + dexamethasone + pomalidomide + daratumumab (SDPd); enrollment complete - Arm 12: Selinexor + dexamethasone + mezigdomide (SMd); actively recruiting Selinexor pharmacokinetics: - PK Run-in (Days 1-14): Starting in protocol version 8.0, patients enrolled to any arm in the Dose Escalation Phase (i.e., Arm 4 [SPVd], Arm 6 [SKd], Arm 8 [SNd], Arm 9 [SPEd], Arm 10 [SBd], and Arm 11 [SDPd]) will also first be enrolled to a pharmacokinetics (PK) Run-in period until 9 patients have been enrolled to this period to evaluate the PK of selinexor before and after co-administration with a strong CYP3A4 inhibitor. This run-in period does not apply to Arm 12 (SMd). Type: Interventional Start Date: Oct 2015 |
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
National Cancer Institute (NCI)
Stage III Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given
together with or without sargramostim and to see how well they work in treating patients
with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may
have spread from where it first... expand
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma. Type: Interventional Start Date: Nov 2015 |
R-P NH of Genetic Vasculopathies
Massachusetts General Hospital
Multisystemic Smooth Muscle Dysfunction Syndrome
This study will combine retrospective review of medical records from patients with ACTA2
and ongoing collection of clinical data using standardized instruments and intervals on
an observational basis from patients with ACTA2.
Patients in cohorts 1-3 will be asked to attend clinic visits in person... expand
This study will combine retrospective review of medical records from patients with ACTA2 and ongoing collection of clinical data using standardized instruments and intervals on an observational basis from patients with ACTA2. Patients in cohorts 1-3 will be asked to attend clinic visits in person per the schedule of events. At minimum, the medical records of patients with ACTA2 will be reviewed to record data on aspects of the disease, including disease characteristics and developmental milestones. The study is planned to enroll a total of 100 patients: 7 in cohort 1, 7 in cohort 2, and the remaining in cohorts 3 and 4. This study is planned to study patients for at least 3 years with the option to continue as long as possible for assessment of disease progression. During their continued study participation, as patients age, they may move into the next cohort. Beyond 3 years the duration of the study with be determined by availability of funding from sponsors. Type: Observational Start Date: May 2024 |
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
Massachusetts General Hospital
Alzheimer Disease
Mild Cognitive Impairment
Logopenic Progressive Aphasia
Amnestic Symptoms
In this research study we want to learn more about the effects of non-invasive brain
stimulation on memory and brain-network function in cognitively unimpaired older adults
and in patients with amnestic mild cognitive impairment (aMCI).
This study will use a form of non-invasive brain stimulation... expand
In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI). This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls memory. Changes resulting from this stimulation will be measured with behavioral tests of memory and general cognition, as well as by taking images of your brain with Magnetic Resonance Imaging (MRI). Participants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit. Type: Interventional Start Date: May 2023 |
PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717.
Ionis Pharmaceuticals, Inc.
Prion Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and
pharmacodynamics of intrathecal (IT) delivery of ION717. expand
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717. Type: Interventional Start Date: Jan 2024 |
Enlighten Study: The EV-ICD Post Approval Registry
Medtronic
Ventricular Arrhythmia
Tachycardia
Medtronic is sponsoring Enlighten: The EV-ICD Post Approval Registry, to further confirm
safety and effectiveness of EV-ICD in routine clinical practice, following commercial
release of EV-ICD devices. expand
Medtronic is sponsoring Enlighten: The EV-ICD Post Approval Registry, to further confirm safety and effectiveness of EV-ICD in routine clinical practice, following commercial release of EV-ICD devices. Type: Observational Start Date: Sep 2023 |
CTSN Embolic Protection Trial
Icahn School of Medicine at Mount Sinai
Delirium
Ischemic Stroke
Acute Kidney Injury
Heart Valve Disease
Coronary Artery Disease
This is a prospective, multi-center, randomized effectiveness trial of the CardioGard
Embolic Protection Cannula in high-risk valve surgery patients. expand
This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients. Type: Interventional Start Date: Sep 2023 |
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may
control evasion of the immune response in tumors. The goal of this clinical trial is to
learn whether NPX267 is safe and tolerable in patients whose cancers are known to express
HHLA2 including epidermal growth... expand
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors. The goal of this clinical trial is to learn whether NPX267 is safe and tolerable in patients whose cancers are known to express HHLA2 including epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer. The main questions it aims to answer are: - what is an appropriate dose to be given to patients? - are the side effects of treatment manageable? Participants will be evaluated for participation in the study. Patients who are treated will receive an intravenous infusion of NPX267 every three weeks if their disease has not progressed. Patients will be closely monitored by the treating physician. Type: Interventional Start Date: Jul 2023 |
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
Calcilytix Therapeutics, Inc., a BridgeBio company
Autosomal Dominant Hypocalcemia (ADH)
The primary purpose of the study is to understand the effectiveness, safety, and
tolerability of encaleret when compared to standard of care (SoC) treatment in
participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1). expand
The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1). Type: Interventional Start Date: Jan 2023 |
Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults
Emalex Biosciences Inc.
Tourette Disorder
This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and
tolerability of ecopipam tablets in children, adolescents and adults in the treatment of
Tourette's Disorder (TD). The study includes an open-label period followed by
double-blind, placebo-controlled, randomized withdrawal... expand
This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults in the treatment of Tourette's Disorder (TD). The study includes an open-label period followed by double-blind, placebo-controlled, randomized withdrawal period. Type: Interventional Start Date: Jan 2023 |
A Diagnostic Test for Dementia With Lewy Bodies
CND Life Sciences
MCI-AD, Early Stage Alzheimer's Disease
MCI-DLB, Early Stage Dementia With Lewy Bodies
The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and
MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing,
earlier diagnosis, and distinguish between neurodegenerative diseases. expand
The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases. Type: Observational Start Date: Aug 2022 |
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory...
Celgene
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion,
first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with
relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed
or refractory higher-risk myelodysplastic syndromes... expand
Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The Dose Escalation part (Part A) of the study will enroll participants with R/R AML and R/R HR-MDS and will evaluate the safety and tolerability of escalating doses of CC-91633 (BMS-986397), administered orally, and determine the maximum tolerated dose (MTD) or preliminary recommended Phase 2 doses (RP2D) and schedule. Throughout the study, final decisions on dose escalation/de-escalation will be made by the safety review committee (SRC). Approximately 60 participants may be enrolled in Part A of the study. The expansion part (Part B) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development. Approximately 60 response-evaluable subjects per indication (R/R AML or R/R HR-MDS) may be enrolled. Parts A and B will consist of 3 periods: Screening, Treatment, and Follow-up. Type: Interventional Start Date: Dec 2021 |
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
Boston Children's Hospital
Graft Vs Host Disease
This is a multicenter randomized, double blind, Phase 2 trial for patients receiving
transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of
abatacept, and a short-term dosing regimen + placebo, when added to standard calcineurin
inhibitor + methotrexate-based prophylaxis,... expand
This is a multicenter randomized, double blind, Phase 2 trial for patients receiving transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of abatacept, and a short-term dosing regimen + placebo, when added to standard calcineurin inhibitor + methotrexate-based prophylaxis, will be compared for their ability to improve outcomes in patients with a minimum follow-up of one year post-transplant. All patients will receive 4 doses of abatacept (Days -1, +5, +14, +28). Prior to the fifth dose, patients will be randomly assigned to the 4-dose abatacept arm and receive 4 doses of placebo or 8-dose abatacept arm and receive 4 more doses of abatacept. The primary endpoint of the study will be severe AGVHD-free, severe CGVHD-free, relapse-free survival (SGRFS). The study will end when the last patient has reached 2 years after transplant. Results will first be calculated and the study unblinded when the last patient has reached one year post-transplant. Type: Interventional Start Date: Mar 2022 |
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
University of Utah
Autoimmune Encephalitis
Encephalitis
Determine the difference in the modified Rankin score at 16 weeks in participants with
anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line"
immunomodulatory therapies provided as standard-of-care, and either inebilizumab
(investigational agent) or placebo. expand
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo. Type: Interventional Start Date: Mar 2022 |
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Constellation Pharmaceuticals
Advanced Solid Tumor
Diffuse Large B Cell Lymphoma
Lymphoma, T-Cell
Mesothelioma, Malignant
Prostatic Neoplasms, Castration-Resistant
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in
patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor
of EZH2. expand
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2. Type: Interventional Start Date: Sep 2019 |
Brain Connectivity in Depression
Brigham and Women's Hospital
Depression
This study originally included 140 subjects with medication-refractory depression
undergoing 10 Hz transcranial magnetic stimulation (10Hz-TMS) to the left dorsal lateral
prefrontal cortex (DLPFC), with the goal of having 60 completers with good quality data.
Subjects were recruited from the TMS clinics... expand
This study originally included 140 subjects with medication-refractory depression undergoing 10 Hz transcranial magnetic stimulation (10Hz-TMS) to the left dorsal lateral prefrontal cortex (DLPFC), with the goal of having 60 completers with good quality data. Subjects were recruited from the TMS clinics at Beth Israel Deaconess Medical Center, Brigham & Women's Hospital, and Butler Hospital. Subjects underwent an hour-long MRI scanning session, an optional DNA-sample collection, up to three 20 minute neuronavigation sessions for marking the site of TMS stimulation, questionnaires, and a behavioral testing battery before and after their TMS treatment course. The task battery included the Emotion Conflict Resolution (ECR) task, Multi-Source Interference Task (MSIT), War Game (Gambling) task, and Associative Learning with Reversal task. Subjects' scores on the Quick Inventory of Depressive Symptomatology (QIDS) and Beck Depression Inventory (BDI) were assessed before and after the TMS course. MRI data was utilized to identify brain regions whose connectivity to the stimulation site co-varies with the aforementioned measures of symptom improvement. This was the only study group until August 30, 2022, and the primary outcome was analyzed for the 10Hz-TMS group. Due to changes in clinical standard of care from 10Hz-TMS to a newer version of TMS termed intermittent theta burst (iTBS), in September 2022 a second group was added to include patients receiving this new form of TMS. This second group included another 100 patients with medication-refractory depression undergoing iTBS to the left dorsal lateral prefrontal cortex (DLPFC), with the intent to have 80 completers. Massachusetts General Hospital was added as a data collection site in lieu of Butler Hospital. Subjects will undergo an hour-long MRI scanning session, up to three 20 minute neuronavigation sessions for marking the site of TMS stimulation, questionnaires, and a behavioral testing battery before and after their TMS treatment course. The task battery will included the Emotion Conflict Resolution (ECR) task, Multi-Source Interference Task (MSIT), Penn Emotion Recognition Test, the Suicide/Death Implicit Association Test, and Associative Learning with Reversal task. Subjects' scores on the Beck Depression Inventory (BDI) were assessed before and after the TMS course. MRI data will be utilized to identify brain regions whose connectivity to the stimulation site co-varies with the aforementioned measures of symptom improvement. Type: Interventional Start Date: Apr 2018 |
National Liver Cancer Screening Trial
University of Texas Southwestern Medical Center
Carcinoma, Hepatocellular
Liver Cancer
Liver Cirrhosis
Hepatitis B
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial
comparing ultrasound-based versus biomarker-based screening in 5500 patients with
cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible
patients will be randomized in a 1:1 fashion to... expand
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), and HCC etiology (viral vs. non-viral). Patients will be recruited from 15 sites (mix of tertiary care and large community health systems) over a 3-year period, and the primary endpoint of the phase IV trial, reduction in late-stage HCC, will be assessed after 5.5 years. Type: Interventional Start Date: Dec 2023 |
Dampening the Reproductive Axis With Continuous Kisspeptin
Stephanie B. Seminara, MD
Reproductive Disorder
PCOS
Polycystic Ovary Syndrome
The goal of this study is to assess response to kisspeptin as well as the baseline
patterns of luteinizing hormone (LH) secretion in individuals with polycystic ovarian
syndrome (PCOS). expand
The goal of this study is to assess response to kisspeptin as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals with polycystic ovarian syndrome (PCOS). Type: Interventional Start Date: Oct 2023 |
Kisspeptin Administration Subcutaneously to Patients With IHH
Stephanie B. Seminara, MD
Hypogonadotropic Hypogonadism
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can
stimulate the release of other reproductive hormones in men and women with idiopathic
hypogonadotropic hypogonadism (IHH). The investigators are also examining whether
kisspeptin can help women release eggs from... expand
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in men and women with idiopathic hypogonadotropic hypogonadism (IHH). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered SC for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth (for women) and frequent blood sampling (every 10 minutes for up to 70 minutes) will be performed to assess the physiologic response to kisspeptin over time. Funding Source: FDA OOPD Type: Interventional Start Date: Feb 2023 |
TRAQinform Assessment of Immunotherapy Response
AIQ Solutions
Melanoma
The intent of this study is to evaluate the actionable information output from the
TRAQinform Immuno technology in a prospective, non-interventional clinical study.
Subjects with metastatic melanoma treated with standard of care (SOC) dual-agent
immunotherapy will be enrolled. Subjects will receive... expand
The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study. Subjects with metastatic melanoma treated with standard of care (SOC) dual-agent immunotherapy will be enrolled. Subjects will receive SOC immunotherapy monitored for treatment response with FDG PET/CT's at baseline (SOC), after 3-4 weeks of treatment (non-SOC) and 12 at weeks of treatment (SOC). Type: Observational Start Date: Jun 2023 |
Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders
Stephanie B. Seminara, MD
Hypothalamic Amenorrhea
Hypogonadotropic Hypogonadism
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can
stimulate the release of other reproductive hormones in women with hypothalamic
amenorrhea (HA). The investigators are also examining whether kisspeptin can help women
release eggs from their ovaries. Kisspeptin... expand
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time. Type: Interventional Start Date: Dec 2022 |
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
Allergy Therapeutics
Peanut Allergy
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP
Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial
will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the
immunotoxicity profile and the degree... expand
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA. Type: Interventional Start Date: Oct 2022 |
- Previous
- Next